Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).

Analysts said Nevro’s valuation was “inexpensive,” but the spinal cord stimulation business can benefit from Globus’ scale ...

aDivision of Neurosurgery, Department of Surgery, University of Toronto, Toronto, ON, Canada bDivision of Neurosurgery, Toronto Western Hospital, University Health Network, Toronto, ON, Canada ...

Your doctor will ensure that the needle is positioned between your spinal cord and the cord’s covering or the meninges when drawing fluid. The whole procedure typically takes about 15 to 20 ...

Nevro NVRO is well-poised for growth in ... However, concerns regarding softness in the spinal cord stimulation (SCS) market and dependence on third-party payers persist. This Zacks Rank #2 ...

Jan. 22, 2015 /PRNewswire/ -- Nevro Corp. (NYSE ... of its Premarket Approval Application (PMA) for the Senza spinal cord stimulation (SCS) system. According to the approvable letter, approval ...

Conventional treatments often have inconsistent efficacy and significant side effects. Combining spinal cord stimulation (SCS) with lidocaine patches may enhance pain relief by targeting central and ...

Doctors informed the media about the surgery, adding that Khan had been moved to the intensive care unit (ICU ... addressed a “spinal fluid leak" caused by the injury. The spinal cord is covered by ...

Nevro NVRO recently announced preliminary ... 2024 primarily due to the impact of greater-than-anticipated spinal cord stimulation (SCS) device replacement procedures in the fourth quarter of ...